Patents Assigned to Entropics Pharmaceuticals, Inc.
  • Methods for determining chemosensitivity and chemotoxicity
    Patent number: 11519015
    Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: December 6, 2022
    Assignee: Entropics Pharmaceuticals, Inc.
    Inventors: William E. Pierceall, Michael H. Cardone